Roles of gastric mucin-type O-glycans in the pathogenesis of Helicobacter pylori infection
Open Access
- 15 January 2009
- journal article
- review article
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 19 (5) , 453-461
- https://doi.org/10.1093/glycob/cwp004
Abstract
Helicobacter pylori is a Gram-negative bacterium that infects over 50% of the world's population. This organism causes various gastric diseases such as chronic gastritis, peptic ulcer, and gastric cancer. H. pylori possesses lipopolysaccharides that share structural similarity to Lewis blood group antigens in gastric mucosa. Such antigenic mimicry could result in immune tolerance against antigens of this pathogen. On the other hand, H. pylori colonizes gastric mucosa by utilizing adhesins that bind Lewis blood group antigen-related carbohydrates expressed on gastric epithelial cells. After colonization, H. pylori induces acute inflammatory responses mainly by neutrophils. This acute phase is gradually replaced by a chronic inflammatory response. In chronic gastritis, lymphocytes infiltrate the lamina propria, and such infiltration is facilitated by the interaction between L-selectin on lymphocytes and peripheral lymph node addressin (PNAd), which contains 6-sulfo sialyl Lewis X-capped O-glycans, on high endothelial venule (HEV)-like vessels. H. pylori barely colonizes gland mucous cell-derived mucin where α1,4-GlcNAc-capped O-glycans exist. In vitro experiments show that α1,4-GlcNAc-capped O-glycans function as a natural antibiotic to inhibit H. pylori growth. These findings show that distinct sets of carbohydrates expressed in the stomach are closely associated with pathogenesis and prevention of H. pylori-related diseases, providing therapeutic potentialities based on specific carbohydrate modulation.Keywords
This publication has 105 references indexed in Scilit:
- Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trialThe Lancet, 2008
- Helicobacter pylori induces β3GnT5 in human gastric cell lines, modulating expression of the SabA ligand sialyl–Lewis xJournal of Clinical Investigation, 2008
- 1,4GlcNAc-capped mucin-type O-glycan inhibits cholesterol -glucosyltransferase from Helicobacter pylori and suppresses H. pylori growthGlycobiology, 2008
- Transgenic expression ofHelicobacter pyloriCagA induces gastrointestinal and hematopoietic neoplasms in mouseProceedings of the National Academy of Sciences, 2008
- Two categories of mammalian galactose-binding receptors distinguished by glycan array profilingGlycobiology, 2006
- Helicobacter pylori and gastrointestinal tract adenocarcinomasNature Reviews Cancer, 2002
- Global cancer statistics in the year 2000The Lancet Oncology, 2001
- GASTRITIS AND GASTRIC CANCERGastroenterology Clinics of North America, 2000
- Specific Detection of Sialyl Lewis X Determinant Carried on the Mucin GlcNAcβ1→6GalNAcα Core Structure as a Tumor-Associated AntigenBiochemical and Biophysical Research Communications, 1998
- EDITORIAL. LYMPHOMAS OF MUCOSA-ASSOCIATED LYMPHOID TISSUE AND ANTIGEN DRIVEThe Journal of Pathology, 1996